Indoco Remedies demonstrates a concerning trend in financial performance. While historical sales growth was reasonable, the TTM sales growth has declined significantly. Profitability has also deteriorated, with negative profit growth in the TTM period. Declining OPM and EPS further confirm these challenges.

The company's sales growth has deteriorated from an average of 16.88% between 2014 and 2016 to -8.38% in Mar 2025. The operating profit margin has also declined significantly, from an average of 17.33% to 6% between the same periods. These trends indicate significant challenges in maintaining revenue and profitability. The YOY sales growth has also been declining since Mar 2022. The net profit has moved from 58 in Mar 2014 to -78 in Mar 2025. The EPS has also fallen to -7.99 in mar 2025. The company's sales growth rate has declined drastically indicating the company's poor performance.

Capital efficiency and returns for Indoco Remedies present a mixed picture. While ROCE has shown some historical strength, recent declines raise concerns about the sustainability of these returns. Asset turnover appears stable, but the increasing cash conversion cycle indicates potential inefficiencies in working capital management.

ROCE has declined from an average of 18.33% (2014-2016) to -0% in Mar 2025, which is a cause for concern. The cash conversion cycle has also increased, indicating that it takes longer for the company to convert its investments in inventory and receivables into cash. This could point to inefficiencies in working capital management.

The financial health of Indoco Remedies shows signs of deterioration. While dividend payouts have been consistent, the increasing debt levels and decreasing interest coverage ratio are concerning. This indicates higher financial leverage and a reduced ability to cover interest obligations.

Borrowings have increased significantly over the years, from an average of 110 (2014-2016) to 994 in Mar 2025. The interest coverage ratio has decreased over time. This combination suggests a higher risk profile due to increased leverage and reduced ability to meet interest payments from operating profit. The increase in long term and short term borrowings indicates the company's increased reliance on debt financing, which could strain its financial resources.

The operational efficiency of Indoco Remedies, as reflected in its working capital management, presents a mixed picture. Debtor days have remained relatively stable, while inventory days have increased significantly. The payable days also increased, partially offsetting the increase in inventory days. Overall, the cash conversion cycle has lengthened, indicating potential inefficiencies in managing working capital.

Inventory days have increased from an average of 167.67 days (2014-2016) to 307 days in Mar 2025, suggesting potential issues with inventory management or demand. The cash conversion cycle has increased from 122 days (Mar 2014) to 232 days (Mar 2025). This indicates that it takes longer for the company to convert its investments in inventory and receivables into cash. This slowdown in the cash conversion cycle could lead to liquidity issues and increased working capital requirements.